Neuroscience this week

Neuroscience This Week: July 26, 2026

Each week Dr. Missios picks a handful of stories, sums them up in plain language and says what he makes of them.

Issue
This issue

July 26, 2026

Dementia and aging
Lab work

A rare gene variant may protect the brain from Alzheimer’s and aging

Researchers studying the APOE2 gene variant, which is already linked to unusually long lifespans, found it appears to help brain cells repair DNA damage and recover from cellular stress more effectively than the common APOE3 or the risk-raising APOE4 variant. The work was done in cell and animal models, not in Alzheimer’s patients directly. The hope is that understanding exactly how APOE2 protects neurons could eventually lead to drugs that mimic its effects in people who carry the higher-risk APOE4 variant. This is basic biology at this stage, aimed at explaining a genetic pattern scientists have observed for years rather than testing a treatment.

Dr. Missios's take

Patients with a family history of Alzheimer’s often ask if their genes are their destiny. This finding does not change that answer yet, since it is laboratory work explaining why a protective gene variant helps, not a drug they can take. If it leads anywhere, it will be years down the road, and the practical advice today remains blood pressure control, exercise, and sleep.

Source: ScienceDaily Neuroscience
Ask about this
Dementia and aging

‘SuperAgers’ with sharp memories in their 80s don’t have unusually good genes

Dr. Missios's take

Families want a simple genetic explanation, either good news or bad news they can plan around, and this study takes that away. The honest message is that we do not yet know why some people stay sharp into their 80s and 90s. Until we do, the boring advice still applies: manage vascular risk factors, stay mentally and socially active, and don’t expect a genetic test to predict your memory.

Two research groups looked at the genetics of ‘SuperAgers,’ older adults who maintain the memory of people decades younger, expecting to find they simply inherited fewer Alzheimer’s risk genes. Instead, their APOE status and overall genetic risk scores looked essentially the same as typical older adults with average memory. That means whatever protects SuperAgers from age-related memory decline is not written in their DNA in any way researchers have yet identified. The real explanation may involve some combination of brain structure, lifestyle, health history, and environment that has not been pinned down

Source: ScienceDaily Neuroscience
Ask about this
Other
Early human studies

A single psilocybin dose may change brain activity for weeks

Dr. Missios's take

People hear about psychedelic research and hope it means a fast, durable fix for depression or anxiety is close at hand. The brain imaging here is genuinely interesting, but this remains early human research with a small sample, not a clinical trial proving a treatment works. Anyone considering psilocybin should do so only inside a supervised research trial, not on the strength of a single imaging study.

In a study of the psychedelic compound psilocybin, researchers measured brain activity before and after a single dose and found changes that persisted for up to a month, along with possible structural changes on brain imaging. Participants whose brain activity became more flexible and varied after the dose were more likely to report personal insight and, later, improvements in general well-being. The study is small and cannot say whether these brain changes caused the reported benefits or simply accompanied them. It adds to a growing body of early human research on psilocybin, but it is not evidence that the drug is an approved or proven treatment for any condition.

Source: ScienceDaily Neuroscience
Ask about this
Dementia and aging

Heavy TV watching in midlife linked to smaller brain regions later in life

Dr. Missios's take

This is the kind of study that gets summarized as ‘TV shrinks your brain,’ and that overstates what an observational study can show. What I take from it is a nudge toward how you spend downtime, not a diagnosis. If you enjoy television, the more useful question is what else fills your day, since mentally engaged and socially active time appears to matter more than the TV itself.

A study of roughly 1,700 adults found that people who watched television very frequently in midlife later showed smaller brain regions involved in memory, decision-making, and visual processing, along with more white matter damage on brain scans. Interestingly, simply sitting for long periods did not show the same association, suggesting something about the passive, engaged nature of heavy TV viewing specifically may matter. This is an observational study, so it cannot prove that television watching itself shrinks the brain rather than reflecting other habits common among heavy viewers. The researchers are careful to frame this as a link worth investigating further, not a settled cause-and-effect finding.

Source: ScienceDaily Neuroscience
Ask about this
Other

Long-term traffic noise exposure linked to higher Parkinson’s risk

Dr. Missios's take

Patients ask me constantly what caused their Parkinson’s, and the honest answer is usually that we don’t know. This study adds traffic noise to a long list of environmental associations, but a 3% relative increase per noise increment is a modest signal from an observational design, not proof of cause. It’s worth further research, but nobody should move house over this finding.

A large study, described as the biggest of its kind, found that people with long-term exposure to road traffic noise had a higher risk of developing Parkinson’s disease, with roughly a 3% increase in risk for every 11.5 decibel rise in noise levels. Parkinson’s is a progressive disease in which brain regions controlling movement and balance gradually deteriorate. The study is observational, meaning it shows an association between noise exposure and Parkinson’s risk but cannot prove that noise itself causes the disease. Researchers suspect chronic noise-related stress and disrupted sleep could plausibly contribute to neurological harm over decades, but the underlying mechanism remains unproven.

Source: The Guardian Science
Ask about this
Spine and nerve
Early human studies

Experimental artery-delivered treatment tested for severe chronic back pain

Dr. Missios's take

I see patients weekly who have run out of standard options for chronic back pain and are desperate for anything that avoids more surgery or more opioids. This is an interesting idea, but it was presented as early clinical experience at a specialty meeting, not as a validated therapy, so I would not offer it outside a trial yet. Worth watching, but years from being something I can recommend.

At a neurointerventional surgery meeting, researchers presented an early technique that delivers medication directly through the arteries supplying painful areas of the spine, aiming to treat severe chronic back pain, which is a leading cause of disability and opioid use. The approach is a newer application of catheter-based techniques already used elsewhere in the body, adapted specifically for spinal pain. Details presented were from an early clinical experience rather than a large randomized trial, so effectiveness and safety over the long term are not yet established. If it pans out, it would offer an alternative pathway for patients who have not responded to physical therapy, injections, or standard surgery.

Source: News-Medical Neurosurgery
Ask about this
Brain tumors
Lab work

New experimental approach aims to make glioblastoma respond to treatment

Dr. Missios's take

I operate on glioblastoma regularly, and I want every one of these early findings to work, because our current options remain limited. The truth is that this is early laboratory testing, and glioblastoma has seen many encouraging lab results that never reached my operating room. I’ll be watching for human trial data before I mention this to a patient.

Scientists at the University of Virginia Comprehensive Cancer Center have developed an experimental strategy targeting glioblastoma, the most common and deadliest primary brain cancer, which has resisted most treatment advances for decades. The approach is described as promising in early laboratory testing, though details on how far it has progressed toward human trials were limited. Glioblastoma remains notoriously difficult to treat because tumor cells infiltrate healthy brain tissue diffusely and because the blood-brain barrier limits how well many drugs reach the tumor. Any new laboratory strategy for this disease is worth tracking, but the history of glioblastoma research is full of promising early findings that did not survive the jump to human patients.

Source: News-Medical
See it in 3DAsk about this
Stroke and vascular
Early human studies

Stroke patients with prior disabilities may still benefit from clot-removal treatment

Dr. Missios's take

Families of patients who already use a wheelchair or need help with daily activities often get told that clot-removal treatment ‘isn’t for them,’ and that conversation is hard. This data suggests that assumption deserves scrutiny, though it comes from an outcomes analysis rather than a trial built to test this question directly. In practice, this pushes me toward evaluating pre-stroke disability patients individually rather than by a blanket rule.

A study presented at a neurointerventional surgery meeting found that stroke patients who already had moderate-to-severe disabilities before their stroke are frequently excluded from endovascular thrombectomy, the procedure that mechanically removes a blood clot causing a large vessel occlusion stroke. The researchers found that many of these excluded patients might still gain meaningful benefit from the procedure, despite the field’s general caution about offering it to people with pre-existing disability. This is a real-world outcomes analysis rather than a randomized trial specifically enrolling disabled patients, so causal conclusions are limited. The findings raise the question of whether current selection criteria for thrombectomy are too conservative for a substantial group of patients.

Source: News-Medical Spine
Ask about this
How close is this to patients? Lab work: tested in cells or animals, not yet in people. Early human studies: first tests in a small number of patients. Proven in trials: shown to work in larger trials, or newly approved. Standard care: already routine treatment or part of a guideline. Tags are a draft for Dr. Missios to review.

News summaries and opinion, not medical advice. Talk to your own doctor about your situation.